FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in PEI as of April 23rd. Please see the following links for full funding criteria:  PEI Pharmacare Bulletin – Pharmacist Bulletin – April 09, 2024 We are excited about these...

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Ontario, Newfoundland and Labrador, and New Brunswick. Please see the following links for full funding criteria: Ontario: Exceptional Access Program | ontario.ca Newfoundland...

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Nova Scotia as of October 1st. Please see the following link for full funding criteria: Nova Scotia Pharmacare News Bulletins Pharmacy Edition (novascotia.ca) We are excited...

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in British Columbia as of October 1, 2023. Further details on the criteria can be found here, under the MYBSD protocol: Lymphoma & Myeloma (bccancer.bc.ca) We are excited...

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Saskatchewan as of September 1st. Please see the following link for full funding criteria: Drug Formulary (saskcancer.ca). We are excited about this important milestone for...

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Alberta as of June 5, 2023. Please see the following link for full funding criteria: AHS Outpatient Cancer Drug Benefit Program 2023-06-05 (albertahealthservices.ca). We are...

(Saint-lgnace-de-Stanbridge, Quebec) May 27th, 2023 – FORUS Therapeutics was a proud sponsor of the 11th Edition of the Défi Cyclo-Myélome. The Défi Cyclo-Myélome provides support to Dr. Richard LeBlanc, holder of the Université de Montréal Myeloma Canada Chair on...

(OAKVILLE, Ontario) May 24, 2023 ­– FORUS Therapeutics Inc ("FORUS") and the pan-Canadian Pharmaceutical Alliance ("pCPA") have completed negotiations with a Letter of Intent (LOI) for XPOVIO®(selinexor) in combination with bortezomib and dexamethasone for the...

(TORONTO, Ontario) April 25-26, 2023 ­– It was an honour to share the FORUS Therapeutics corporate update on April 25 at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto. We are very proud of the important commercialization milestones our team...

FORUS Therapeutics is delighted to welcome Vania Brennan as Therapeutic Area Manager, Hematology/Oncology, BC/AB.  Vania is well recognized as a therapeutic expert in the field of hematology and oncology with over 20 years experience in this space, in commercial and...

FORUS Therapeutics is delighted to welcome Nancy Davies as Therapeutic Area Manager, Hematology/Oncology, GTA W/Southwest ONT.  Nancy brings to this role her significant experience across various therapeutic areas, with a long history and passion for...

FORUS Therapeutics is delighted to welcome Michel St-Pierre as Therapeutic Area Manager, Hematology/Oncology, Quebec.  Michel brings with him extensive experience across commercial roles in the health care industry, including business development and commercial sales,...